The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.
Marc Ladanyi
Consultant or Advisory Role - NanoString Technologies
Honoraria - Abbott Molecular (I); Sequenom Center for Molecular Medicine
Phil T. Cagle
No relevant relationships to disclose
Mary Beth Beasley
No relevant relationships to disclose
Dhananjay Chitale
No relevant relationships to disclose
Sanja Dacic
No relevant relationships to disclose
Giuseppe Giaccone
No relevant relationships to disclose
Robert B. Jenkins
No relevant relationships to disclose
David J. Kwiatkowski
Consultant or Advisory Role - ArQule; Novartis
Honoraria - Millennium; NanoString Technologies
Juan-Sebastian Saldivar
Employment or Leadership Position - City of Hope Medical Group; Existence Genetics; Sequenom Center for Molecular Medicine
Jeremy Squire
Consultant or Advisory Role - Applied SpectraI Imaging; CymoGen Dx
Erik Thunnissen
Consultant or Advisory Role - Lilly; Merck; Pfizer
Neal Ian Lindeman
No relevant relationships to disclose